Asset Details
Do you wish to reserve the book?
Adaptive methods help drug sponsors find best treatment dose
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adaptive methods help drug sponsors find best treatment dose
Do you wish to request the book?
Adaptive methods help drug sponsors find best treatment dose
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adaptive methods help drug sponsors find best treatment dose
2014
Overview
Across the drug industry, around 20% of clinical trials now involve some element of adaptive design, in which researchers make preplanned adjustments to protocols at interim checkpoints. The idea is to save both time and money, helping drug developers collect data and modify parameters midstudy. But while adaptive trials have commonly involved simple changesmostly futility analyses or sample size reestimationsa new effort is underway to facilitate more sophisticated adjustments to drug dosages in these types of clinical studies. On 18 February, three large pharmaceutical companies and a contract research organization (CRO) specializing in adaptive trial design announced a new coalition with this aim. The ADDPLAN DF Consortium so far includes Novartis, Janssen Pharmaceuticals and Eli Lilly. Four other major drugmakers are also in discussions about joining.
Publisher
Nature Publishing Group US,Nature Publishing Group
